NCT00760955 - Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy | Biotech Hunter

Enrollment

338

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions

Diabetic Neuropathies

Interventions

DRUG

TAK-583

TAK-583 5 mg, tablets, orally, once daily for up to 6 months.

DRUG

TAK-583

TAK-583 50 mg, tablets, orally, once daily for up to 6 months.

DRUG

TAK-583

TAK-583 100 mg, tablets, orally, once daily for up to 6 months.

DRUG

Placebo

TAK-583 placebo-matching tablets, orally, once daily for up to 6 months.

Trial Locations (38)

Unknown

Mesa

Peoria

Phoenix

Tucson

Jonesboro

Huntington Beach

La Jolla

Los Angeles

Pasadena

Tustin

Largo

Miami

New Port Richey

Palm Beach Gardens

Sunrise

West Palm Beach

Decatur

Idaho Falls

Chicago

Boston

Ann Arbor

Las Vegas

Englewood

Buffalo

Staten Island

Greenville

Cleveland

Portland

Duncansville

Dallas

Houston

San Antonio

Norfolk

Vancouver

Kingston

North Bay

Laval

Québec